nmda receptor selective antagonist ly235959 Search Results


ly 235959  (MuseChem Chemicals)
N/A
LY235959 (Cat.No:I007799) is a selective and potent antagonist of the NMDA (N-methyl-D-aspartate) receptor subtype 2B (NR2B). It is a small molecule compound that has been extensively studied for its potential use in the treatment of
   Buy from Supplier
ly 235959  (TargetMol)
N/A
   Buy from Supplier
nmda antagonist ly235959  (Tocris)
97
Tocris nmda antagonist ly235959
All data are presented as mean (± SEM) number of nicotine infusions earned. (a) Lidocaine infused into IPN increased nicotine intake in rats; **P<0.01. (b) Lidocaine into MHb increased nicotine intake in rats self-administering a high unit dose (0.12 mg kg −1 per infusion); *P<0.05. (c) <t>LY235959</t> infused into IPN increased nicotine intake in rats ( n =9). F (3,24) =6.08, p<0.01. *P<0.05 and **p<0.01 compared to control. (d) LY235959 (10 ng/side) into MHb increased nicotine intake in rats responding for a high unit dose (0.12 mg kg −1 per infusion; n=5); *P<0.05.
Nmda Antagonist Ly235959, supplied by Tocris, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptor+selective+antagonist+ly235959/pmc03079537-112-1-4?v=Tocris
Average 97 stars, based on 1 article reviews
nmda antagonist ly235959 - by Bioz Stars, 2026-08
97/100 stars
  Buy from Supplier
ly235959  (Federation of European Neuroscience Societies)
90
Federation of European Neuroscience Societies ly235959
All data are presented as mean (± SEM) number of nicotine infusions earned. (a) Lidocaine infused into IPN increased nicotine intake in rats; **P<0.01. (b) Lidocaine into MHb increased nicotine intake in rats self-administering a high unit dose (0.12 mg kg −1 per infusion); *P<0.05. (c) <t>LY235959</t> infused into IPN increased nicotine intake in rats ( n =9). F (3,24) =6.08, p<0.01. *P<0.05 and **p<0.01 compared to control. (d) LY235959 (10 ng/side) into MHb increased nicotine intake in rats responding for a high unit dose (0.12 mg kg −1 per infusion; n=5); *P<0.05.
Ly235959, supplied by Federation of European Neuroscience Societies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptor+selective+antagonist+ly235959/pm24467279-92-0-35?v=Federation+of+European+Neuroscience+Societies
Average 90 stars, based on 1 article reviews
ly235959 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
ly235959  (Eli Lilly)
86
Eli Lilly ly235959
All data are presented as mean (± SEM) number of nicotine infusions earned. (a) Lidocaine infused into IPN increased nicotine intake in rats; **P<0.01. (b) Lidocaine into MHb increased nicotine intake in rats self-administering a high unit dose (0.12 mg kg −1 per infusion); *P<0.05. (c) <t>LY235959</t> infused into IPN increased nicotine intake in rats ( n =9). F (3,24) =6.08, p<0.01. *P<0.05 and **p<0.01 compared to control. (d) LY235959 (10 ng/side) into MHb increased nicotine intake in rats responding for a high unit dose (0.12 mg kg −1 per infusion; n=5); *P<0.05.
Ly235959, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptor+selective+antagonist+ly235959/pm09272810-52-0-5?v=Eli+Lilly
Average 86 stars, based on 1 article reviews
ly235959 - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
ly 235959  (Santa Cruz Biotechnology)
N/A
LY 235959 has been shown to act as a competitive NMDA receptor antagonist.
   Buy from Supplier
ly 235959  (Tocris)
N/A
Competitive NMDA antagonist
   Buy from Supplier
ly 235959  (BOC Sciences)
N/A
LY 235959 is a competitive N-Methyl-D-Aspartate Receptor antagonist originated by Eli Lilly. No development was reported for treatment of Movement disorders in USA . Research for treatment of Alzheimer's disease was discontinued.
   Buy from Supplier

Image Search Results


All data are presented as mean (± SEM) number of nicotine infusions earned. (a) Lidocaine infused into IPN increased nicotine intake in rats; **P<0.01. (b) Lidocaine into MHb increased nicotine intake in rats self-administering a high unit dose (0.12 mg kg −1 per infusion); *P<0.05. (c) LY235959 infused into IPN increased nicotine intake in rats ( n =9). F (3,24) =6.08, p<0.01. *P<0.05 and **p<0.01 compared to control. (d) LY235959 (10 ng/side) into MHb increased nicotine intake in rats responding for a high unit dose (0.12 mg kg −1 per infusion; n=5); *P<0.05.

Journal: Nature

Article Title: Habenular α5* nicotinic receptor signaling controls nicotine intake

doi: 10.1038/nature09797

Figure Lengend Snippet: All data are presented as mean (± SEM) number of nicotine infusions earned. (a) Lidocaine infused into IPN increased nicotine intake in rats; **P<0.01. (b) Lidocaine into MHb increased nicotine intake in rats self-administering a high unit dose (0.12 mg kg −1 per infusion); *P<0.05. (c) LY235959 infused into IPN increased nicotine intake in rats ( n =9). F (3,24) =6.08, p<0.01. *P<0.05 and **p<0.01 compared to control. (d) LY235959 (10 ng/side) into MHb increased nicotine intake in rats responding for a high unit dose (0.12 mg kg −1 per infusion; n=5); *P<0.05.

Article Snippet: The NMDA antagonist LY235959 (Tocris, Ellisville, MO) or lidocaine (2%, Sigma Chemical Co.) were microinjected at a volume of 0.5 μl for over 1 min, and the injector remained in place for an additional 2 min to allow for diffusion.

Techniques: Control